التفاصيل البيبلوغرافية
العنوان:
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
المؤلفون:
Tanya Simuni , Holly A. Shill , Matthew Brodsky , Marcie Rabin , Michael A. Schwarzschild , Kenneth Marek , Cheryl Waters , Cindy Casaceli , Steven A. Gunzler , Stephen G. Reich , Codrin Lungu , Sarah Elizabeth Zauber , Kellie Keith , Shyamal H. Mehta , Dariush Mozaffarian , Valerie Suski , Marie Saint-Hilaire , John L. Goudreau , Alice Rudolph , Ruth B. Schneider , Aaron Daley , Eric A. Macklin , Zoltan Mari , Grace F. Crotty , Andres Deik , Alberto J. Espay , Ashley Laroche , Sherri Mosovsky , Joohi Jimenez-Shahed , Mark S. LeDoux , Cynthia Poon , Ashley Gerald , John C. Morgan , Carolyn Peterson , Joseph H. Friedman , David Klements , Robert A. Hauser , Doozie Russell , David Simon , Kathrin LaFaver , Vanessa K. Hinson , Richard B. Dewey , Melissa Ainslie , Jason Aldred , Tiago A. Mestre , John Y. Fang , Liana S. Rosenthal , Grace Bwala , Raymond C. James , Binit B. Shah , Gearoid M. McMahon , Ariane Park , Rajeev Kumar , Lin Zhang , Ivan Bodis-Wollner , Mya C. Schiess , Katherine F. Callahan , David Oakes , Kelvin L. Chou , Melissa Kostrzebski , Roger Kurlan , Lisa Gauger , Albert Y. Hung , Melissa Bixby , Ira Shoulson , Michael Soileau , James T. Boyd , Peter A LeWitt , Burton L. Scott , Claire Henchcliffe , Patricia Kaminski , Alberto Ascherio , Cornelia Kamp , Lindsay Pothier , Anwar Ahmed , Jill Ciccarello , David J. Houghton , April Langhammer , Rebecca Fitzgerald , Maureen A. Leehey , Anthony E. Lang , Carmen Serrano , Martha McGraw , David Shprecher , Jennifer Durphy , Aleksandar Videnovic , Danish Bhatti , Christine Hunter , Amber Servi Ratel , J. Antonelle de Marcaida , Christopher G. Goetz , Emily Houston , Rajesh Pahwa , Chadwick W. Christine , Gary C. Curhan , Irene Litvan , Christopher A. Beck , Leslie J. Cloud , Patrick Bolger , Karen Thomas , Natividad Stover , Karen Blindauer , Sushrut S. Waikar , Susan R. Criswell
المصدر:
JAMA
بيانات النشر:
American Medical Association, 2021.
سنة النشر:
2021
مصطلحات موضوعية:
medicine.medical_specialty , business.industry , Dopaminergic , Unified Parkinson's disease rating scale , General Medicine , Placebo , law.invention , Clinical trial , Randomized controlled trial , law , Internal medicine , Severity of illness , medicine , Inosine , business , Adverse effect , medicine.drug , Original Investigation
الوصف:
IMPORTANCE: Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical data. OBJECTIVE: To determine whether sustained urate-elevating treatment with the urate precursor inosine slows early PD progression. DESIGN, PARTICIPANTS, AND SETTING: Randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in early PD. A total of 587 individuals consented, and 298 with PD not yet requiring dopaminergic medication, striatal dopamine transporter deficiency, and serum urate below the population median concentration (
اللغة:
English
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e4608ea519947a922d23da1991ccca9Test https://europepmc.org/articles/PMC8441591Test /
حقوق:
OPEN
رقم الانضمام:
edsair.doi.dedup.....9e4608ea519947a922d23da1991ccca9
قاعدة البيانات:
OpenAIRE
